144 related articles for article (PubMed ID: 2900291)
1. Receptor changes during chronic dopaminergic stimulation.
Jenner P; Boyce S; Marsden CD
J Neural Transm Suppl; 1988; 27():161-75. PubMed ID: 2900291
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
4. Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors.
Rouillard C; Bédard PJ; Falardeau P; Dipaolo T
Neuropharmacology; 1987 Nov; 26(11):1601-6. PubMed ID: 3431663
[TBL] [Abstract][Full Text] [Related]
5. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD
Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859
[TBL] [Abstract][Full Text] [Related]
6. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
7. The effects on central dopamine function of chronic L-dopa (methyl ester hydrochloride) treatment of mice.
Tabar J; Hashizume M; Cook CJ; Beart PM; Jackson DM
Pharmacol Biochem Behav; 1989 May; 33(1):139-46. PubMed ID: 2789405
[TBL] [Abstract][Full Text] [Related]
8. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Blunt S; Jenner P; Marsden CD
Neuroscience; 1991; 40(2):453-64. PubMed ID: 1902916
[TBL] [Abstract][Full Text] [Related]
9. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa.
Blunt SB; Jenner P; Marsden CD
Brain Res; 1992 Jun; 582(2):299-311. PubMed ID: 1393551
[TBL] [Abstract][Full Text] [Related]
10. The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
Globus M; Bannet J; Lerer B; Belmaker RH
Psychopharmacology (Berl); 1982; 78(1):81-4. PubMed ID: 6815701
[TBL] [Abstract][Full Text] [Related]
11. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.
Bychkov E; Ahmed MR; Dalby KN; Gurevich EV
J Neurochem; 2007 Aug; 102(3):699-711. PubMed ID: 17630981
[TBL] [Abstract][Full Text] [Related]
12. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
[TBL] [Abstract][Full Text] [Related]
13. Dopamine receptor changes in response to prolonged treatment with L-dopa.
Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
[TBL] [Abstract][Full Text] [Related]
14. Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
Groppetti A; Ceresoli G; Mandelli V; Parenti M
J Pharmacol Exp Ther; 1990 Jun; 253(3):950-6. PubMed ID: 2162953
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of repeated treatment with L-dopa on dopamine-D1 or -D2 receptors.
Parenti M; Flauto C; Parati E; Vescovi A; Groppetti A
Neuropharmacology; 1986 Mar; 25(3):331-4. PubMed ID: 2871516
[TBL] [Abstract][Full Text] [Related]
16. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
[TBL] [Abstract][Full Text] [Related]
17. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
Arnt J
Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
[TBL] [Abstract][Full Text] [Related]
18. The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study.
Gnanalingham KK; Robertson RG
Brain Res; 1994 Mar; 640(1-2):185-94. PubMed ID: 8004447
[TBL] [Abstract][Full Text] [Related]
19. Repeated stimulation of D-1 dopamine receptors increases the circling response to bromocriptine in rats with a 6-OHDA lesion.
Rouillard C; Bédard P; Falardeau P; Di Paolo T
Eur J Pharmacol; 1988 Nov; 157(2-3):125-33. PubMed ID: 2975996
[TBL] [Abstract][Full Text] [Related]
20. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
